Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. November 2015 09:22 ET | Quelle: Curis, Inc.

Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
02. November 2015 07:00 ET | Quelle: Curis, Inc.

Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
02. November 2015 06:30 ET | Quelle: Curis, Inc.

Curis to Release Third Quarter 2015 Financial Results and Hold Conference Call on November 9, 2015

LEXINGTON, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
19. Oktober 2015 07:00 ET | Quelle: Curis, Inc.

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

Company exercises options under Aurigene collaboration to license orally available small molecules for immuno-oncology and precision oncology Curis selects program of small molecules targeting...
14. Oktober 2015 07:00 ET | Quelle: Curis, Inc.

Curis to Present at the BIO Investor Forum

LEXINGTON, Mass., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
02. September 2015 07:00 ET | Quelle: Curis, Inc.

Curis to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
06. August 2015 07:00 ET | Quelle: Curis, Inc.

Curis Reports Second Quarter 2015 Financial Results

LEXINGTON, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
30. Juli 2015 07:00 ET | Quelle: Curis, Inc.

Curis to Release Second Quarter 2015 Financial Results and Hold Conference Call on August 6, 2015

LEXINGTON, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
10. Juni 2015 07:00 ET | Quelle: Curis, Inc.

Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma

LEXINGTON, Mass., June 10, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment...
31. Mai 2015 09:00 ET | Quelle: Curis, Inc.

Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting

--CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including Complete Responses, in Patients With Relapsed/ Refractory DLBCL-- --Expansion Phase Ongoing in Patients With...

Vorherige Seite

Nächste Seite